Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Debt: 2013-2025

Historic Non-Current Debt for Ironwood Pharmaceuticals (IRWD) over the last 9 years, with Sep 2025 value amounting to $385.0 million.

  • Ironwood Pharmaceuticals' Non-Current Debt fell 3.75% to $385.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $385.0 million, marking a year-over-year decrease of 3.75%. This contributed to the annual value of $385.0 million for FY2024, which is 28.33% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Non-Current Debt is $385.0 million, which was down 0.00% from $385.0 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Non-Current Debt's 5-year high stood at $425.0 million during Q2 2024, with a 5-year trough of $275.0 million in Q1 2024.
  • In the last 3 years, Ironwood Pharmaceuticals' Non-Current Debt had a median value of $385.0 million in 2025 and averaged $366.5 million.
  • Within the past 5 years, the most significant YoY rise in Ironwood Pharmaceuticals' Non-Current Debt was 40.00% (2025), while the steepest drop was 9.41% (2025).
  • Ironwood Pharmaceuticals' Non-Current Debt (Quarterly) stood at $300.0 million in 2023, then grew by 28.33% to $385.0 million in 2024, then declined by 3.75% to $385.0 million in 2025.
  • Its last three reported values are $385.0 million in Q3 2025, $385.0 million for Q2 2025, and $385.0 million during Q1 2025.